Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Operating Expenses: 2022-2025

Historic Operating Expenses for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to $217.1 million.

  • Axsome Therapeutics' Operating Expenses rose 29.70% to $217.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $773.7 million, marking a year-over-year increase of 20.01%. This contributed to the annual value of $666.3 million for FY2024, which is 32.61% up from last year.
  • Latest data reveals that Axsome Therapeutics reported Operating Expenses of $217.1 million as of Q3 2025, which was up 16.25% from $186.8 million recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Operating Expenses ranged from a high of $217.1 million in Q3 2025 and a low of $38.3 million during Q1 2022.
  • Over the past 3 years, Axsome Therapeutics' median Operating Expenses value was $167.4 million (recorded in 2024), while the average stood at $159.2 million.
  • Data for Axsome Therapeutics' Operating Expenses shows a peak YoY surged of 163.65% (in 2023) over the last 5 years.
  • Quarterly analysis of 4 years shows Axsome Therapeutics' Operating Expenses stood at $84.3 million in 2022, then spiked by 101.45% to $169.8 million in 2023, then climbed by 12.71% to $191.4 million in 2024, then increased by 29.70% to $217.1 million in 2025.
  • Its Operating Expenses stands at $217.1 million for Q3 2025, versus $186.8 million for Q2 2025 and $178.4 million for Q1 2025.